PMID- 10779813
OWN - NLM
STAT- MEDLINE
DCOM- 20000504
LR  - 20181130
IS  - 0007-4551 (Print)
IS  - 0007-4551 (Linking)
VI  - 87
IP  - 3
DP  - 2000 Mar
TI  - [Phase II study of docetaxel in inoperable advanced non small cell lung cancer].
PG  - 253-8
AB  - The purpose is to determine the response to, and toxicity of docetaxel (Taxotere) 
      in patients with inoperable non small cell lung cancer (NSCLC), previously 
      untreated. Seventy patients with stage IIIB or IV NSCLC were treated by 100 
      mg/m2/ 3 weeks of docetaxel until tumor progression or severe toxicity. 
      Premedication with diosmine and prednisolone was given in all patients: 66/70 
      were eligible and 55/70 were assessable for antitumoral activity. Median age: 63 
      years, WHO performans status 0-1: 83%, stage IV: 96%. For eligible patients, 
      17/66 (26%) achieved an objective response: 1 complete response and 16 partial 
      response (IC 95% = 15-36). With a median follow-up of 23.4 months (range 
      14.9-28.7), for evaluable patients, the median response duration was 8 months, 
      the median time to progression 4 months, and the median survival time 10 months. 
      The median number of administered cycles is 5 (range 1-12). The estimate one year 
      survival rate was 47%. Seventy-six patients presented neutropenia (grade 3-4); 
      febrile neutropenia was observed in 7% of cycles. Non haematological toxicities 
      are: fluid retention related to docetaxel (2.9%), diarrhea (6%), nausea-vomiting 
      (4%), asthenia (3%), nail changes (6%). Docetaxel (Taxotere) administered at 100 
      mg/m2/3 weeks has relevant clinical activity in previously untreated NSCLC with a 
      acceptable toxicity.
FAU - Robinet, G
AU  - Robinet G
AD  - Service d'oncologie thoracique, Hopital Morvan, 5, avenue Foch, 29609 Brest, 
      France.
FAU - Thomas, P
AU  - Thomas P
FAU - Perol, M
AU  - Perol M
FAU - Vergnenegre, A
AU  - Vergnenegre A
FAU - Lena, H
AU  - Lena H
FAU - Taytard, A
AU  - Taytard A
FAU - Paillotin, D
AU  - Paillotin D
FAU - Bessa, E H
AU  - Bessa EH
FAU - Schuller-Lebeau, M P
AU  - Schuller-Lebeau MP
LA  - fre
PT  - Clinical Trial
PT  - Clinical Trial, Phase II
PT  - Journal Article
PT  - Multicenter Study
TT  - Etude de phase II: docetaxel dans les cancers bronchopulmonaires non a petites 
      cellules inoperables.
PL  - France
TA  - Bull Cancer
JT  - Bulletin du cancer
JID - 0072416
RN  - 0 (Antineoplastic Agents, Phytogenic)
RN  - 0 (Taxoids)
RN  - 15H5577CQD (Docetaxel)
RN  - P88XT4IS4D (Paclitaxel)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Antineoplastic Agents, Phytogenic/*administration & dosage/adverse effects
MH  - Carcinoma, Non-Small-Cell Lung/*drug therapy
MH  - Docetaxel
MH  - Female
MH  - Humans
MH  - Lung Neoplasms/*drug therapy
MH  - Male
MH  - Middle Aged
MH  - Paclitaxel/administration & dosage/adverse effects/*analogs & derivatives
MH  - *Taxoids
EDAT- 2000/04/26 09:00
MHDA- 2000/05/16 09:00
CRDT- 2000/04/26 09:00
PHST- 2000/04/26 09:00 [pubmed]
PHST- 2000/05/16 09:00 [medline]
PHST- 2000/04/26 09:00 [entrez]
PST - ppublish
SO  - Bull Cancer. 2000 Mar;87(3):253-8.